Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘tissue resident memory cells’

Leaves of grass

Fall leaves in Boston

Autumn (or Fall for our American readers) is a time of cyclical renewal as old leaves die off and fall by the wayside to make way for new growth to emerge.

It’s the same process in oncology R&D pipelines too; by 4th quarter earnings reports we start to see Product X or Y being officially discontinued/abandoned, or sent off silently to dog drug heaven without even an epitaph to claim.

What about the promised new growth opportunities or targets?

Well there are various cancer conferences either happening now or coming up, which should offer plenty of signals for hope amongst SITC, EBCC, SABCS, ESMO IO, with ASH signing off the final coverage of the year.

In our latest report, we highlight some key presentations to watch out for not covered in the earlier SITC previews.  Some look encouraging already, while others – in all fairness – may have some unexpected question marks to consider…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

An immunotherapy for the long run – or tail

With SITC fast coming up this week, immunotherapies in all sorts of shapes and guises are very much going to be at the forefront of many people’s attention.

The Fall conference season is in full swing – time to take a look at an emerging new development

Aside from various well established approaches though, is there anything new on the horizon?

It turns out there is something that caught our imagination at BSB.

The good news it’s not yet another X checkpoint inhibitor/immune agonist/cytokine – this concept is both a novel and a compelling one.

It also potentially fills a need not addressed by the other approaches.

Want to learn more about this intriguing approach based on rationally driven science?

BSB subscribers can read up on our ongoing commentary and analysis from the cancer conference season – you can either log-in or click to access our latest analysis.

This content is restricted to subscribers

A rock around the breast cancer clock

Sadly not the #blisterwalk this year

Not in Chicago – Breast cancer has been a hot topic again on several fronts after a bit of a lull on the R&D front.

Writing about such trials across ESMO Breast, ASCO and the second AACR meeting is all very well, but what about some KOL commentary and reactions to some of the data we get to see?

If this has been a burning question for you, this is a handy article to catch up on. Of course, to be clear – not all the trials will be positive or biomarker analysis helpful, so here we tackle the issue and look at what’s what though the lens of a specialist…

To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the ESMO Breast, ASCO and second AACR meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

ASH18 Highlights from Day 2

For today’s post, we’ve curated our individual highlights from the tsunami of data that flew thick and fast yesterday between science sessions, oral presentations and poster hall gems.

There were some pleasant surprises in the mix, to be sure, plus the weather brightened up immeasurably!

Yesterday’s lunch time ASH Dash was quieter than usual

Having whittled the number of trial highlights for review and critique down to thirteen key insights and learnings, what made our joint list?

To find out more, check out the post below!

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

CICON18 Day 1 Highlights

Heading Downtown for #CICON18

New York – It’s always good to see cancer researchers receive a Nobel prize.

I don’t think anyone at #CICON18 was surprised to see Dr Jim Allison as a recipient.  I’m delighted to see Prof Honjo was also recognised too, as he discovered the PD-1 checkpoint target:

Moving on it’s time for some highlights of the first day of the meeting – a couple of interesting findings emerged from the proceedings…

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!